Vilafinil: Enhance Cognitive Performance Safely and Effectively
| Product dosage: 200 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.86 | $55.90 (0%) | 🛒 Add to cart |
| 60 | $1.15 | $111.80 $68.80 (38%) | 🛒 Add to cart |
| 100 | $0.81 | $186.33 $80.84 (57%) | 🛒 Add to cart |
| 200 | $0.75 | $372.67 $150.50 (60%) | 🛒 Add to cart |
| 300 | $0.69 | $559.00 $208.12 (63%) | 🛒 Add to cart |
| 500 | $0.65
Best per pill | $931.67 $322.50 (65%) | 🛒 Add to cart |
Vilafinil is a high-quality generic pharmaceutical formulation of modafinil, a wakefulness-promoting agent and cognitive enhancer approved for medical use. Developed to meet rigorous manufacturing standards, Vilafinil offers a reliable therapeutic option for managing excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. Its mechanism of action differs from traditional stimulants, providing sustained alertness without significant euphoric effects or rebound fatigue. Clinical evidence supports its efficacy in improving wakefulness, executive function, and overall cognitive performance in appropriate patient populations.
Features
- Contains 200 mg modafinil per tablet
- Manufactured under GMP (Good Manufacturing Practice) standards
- Bioequivalent to brand-name modafinil formulations
- Long duration of action (up to 12-15 hours)
- Minimal cytochrome P450 enzyme inhibition compared to older stimulants
- Low abuse potential classification (Schedule IV controlled substance)
Benefits
- Promotes sustained wakefulness without typical stimulant side effects
- Enhances cognitive function including memory, attention, and executive processing
- Improves quality of life for individuals with sleep disorders
- Reduces excessive daytime sleepiness with once-daily dosing
- Maintains alertness during night shifts or prolonged wakefulness
- Minimal impact on cardiovascular parameters compared to amphetamine-based stimulants
Common use
Vilafinil is primarily prescribed for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS), and shift work sleep disorder (SWSD). In clinical practice, it has also shown benefit for improving wakefulness in patients with residual sleepiness despite adequate treatment of OSAHS with continuous positive airway pressure (CPAP). Off-label uses include adjunctive treatment for fatigue associated with multiple sclerosis, depression, and other medical conditions, though these applications require careful medical supervision and are not FDA-approved indications.
Dosage and direction
The recommended dosage for Vilafinil is 200 mg taken orally once daily in the morning for narcolepsy or OSAHS. For shift work sleep disorder, take approximately one hour before the start of the work shift. The maximum recommended daily dose is 400 mg, though most patients respond adequately to 200 mg daily. Tablets should be swallowed whole with water and may be taken with or without food, though food may delay absorption slightly. Dosage adjustment is recommended in elderly patients and those with severe hepatic impairment, with a reduced initial dose of 100 mg daily. Treatment should begin at the lowest effective dose and be periodically reevaluated for continued necessity.
Precautions
Patients should be monitored for the development of hypersensitivity reactions, including serious skin rashes such as Stevens-Johnson syndrome. Psychiatric symptoms including anxiety, agitation, insomnia, and depression should be carefully assessed, particularly in patients with pre-existing psychiatric conditions. Cardiovascular status should be evaluated in patients with history of left ventricular hypertrophy, mitral valve prolapse, or other structural cardiac abnormalities. Vilafinil may reduce the effectiveness of hormonal contraceptives; alternative or additional methods of contraception are recommended during and for one month after treatment. Patients should avoid alcohol consumption while taking Vilafinil as it may alter tolerance and effects.
Contraindications
Vilafinil is contraindicated in patients with known hypersensitivity to modafinil, armodafinil, or any component of the formulation. It should not be used in patients with symptomatic ischemic heart disease, uncompensated heart failure, significant cardiac arrhythmias, or history of myocardial infarction. Use is contraindicated in patients with severe hypertension that is not adequately controlled. Vilafinil is not recommended for patients with history of psychosis or manic episodes. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to potential hypertensive crisis.
Possible side effects
Common adverse reactions (≥5%) include headache, nausea, nervousness, anxiety, insomnia, dizziness, and diarrhea. Less frequently reported effects include dry mouth, decreased appetite, palpitations, hypertension, and visual disturbances. Serious but rare side effects may include severe skin reactions, angioedema, multi-organ hypersensitivity reactions, psychiatric symptoms including psychosis and mania, and cardiovascular events. Most side effects are dose-dependent and often diminish with continued therapy. Patients should report any persistent or severe adverse effects to their healthcare provider promptly.
Drug interaction
Vilafinil exhibits complex pharmacokinetic interactions as a weak inducer of CYP3A4 and inhibitor of CYP2C19. It may decrease plasma concentrations of drugs metabolized by CYP3A4, including ethinyl estradiol (oral contraceptives), cyclosporine, midazolam, and triazolam. Concurrent use with CYP2C19 substrates such as diazepam, phenytoin, or propranolol may increase their plasma concentrations. Vilafinil may interact with warfarin, requiring more frequent monitoring of prothrombin time. Concomitant use with MAOIs is contraindicated. Caution is advised when combining with other CNS stimulants or sympathomimetic agents.
Missed dose
If a dose is missed, it should be taken as soon as possible on the same day. However, if it is approaching evening hours, the missed dose should be skipped to prevent insomnia. Doubling the dose to make up for a missed dose is not recommended. For shift work disorder patients who miss their pre-shift dose, taking Vilafinil later in the shift is generally not advised due to potential interference with subsequent sleep periods. Consistent daily timing is important for maintaining therapeutic effects and minimizing sleep disruption.
Overdose
Symptoms of overdose may include insomnia, central nervous system excitation, agitation, anxiety, confusion, tachycardia, hypertension, and gastrointestinal distress. In cases of significant overdose, more severe manifestations including hallucinations, psychosis, and cardiovascular effects may occur. Management involves symptomatic and supportive care, including cardiac monitoring and appropriate treatment of symptoms. There is no specific antidote for modafinil overdose. Gastric lavage may be considered if presentation is early after ingestion. Hemodialysis is unlikely to be effective due to high protein binding.
Storage
Store Vilafinil tablets at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations, typically through medication take-back programs or by mixing with undesirable substance and placing in sealed container.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Vilafinil is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to medication may vary, and proper diagnosis and monitoring are essential. The information presented here is not exhaustive; patients should consult their healthcare provider for complete prescribing information and personalized medical advice. Never initiate or discontinue medication without professional guidance.
Reviews
Clinical studies demonstrate Vilafinil’s efficacy in maintaining wakefulness, with 64-74% of patients showing significant improvement in sleep latency tests compared to placebo. Patient reports frequently note improved ability to maintain attention during monotonous tasks and reduced sleep attacks in narcolepsy. Some users report mild headache or nausea during the initial treatment period, which typically resolves with continued use. Healthcare providers note the favorable side effect profile compared to traditional stimulants, though emphasize the importance of cardiovascular and psychiatric monitoring. Long-term users appreciate the consistent cognitive benefits with minimal development of tolerance when used as prescribed.